Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

Inclusion Criteria: Participants who: * Diagnosis of primary open angle glaucoma. * Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye. Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg. * Corrected visual acuity in each eye greater than or equal to +0.3logMAR. * Minimum central endothelial cell density of greater than or equal to 1600 cells per mm2 * Currently managing their POAG with IOP lowering drop therapy. Exclusion Criteria: Participants who: * Have pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. * Have a history of or current ocular inflammation. * Have aphakic eyes or only one eye. * Recent surgery in the study eye surgery (including laser). * Clinically significant ocular disease in either eye (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca or infection) which might interfere with the study. * Known sensitivity to any component of the product (e.g. latanoprost or polytriazole sensitivity), or to topical therapy used during course of study (e.g. povidone iodine, or anaesthetics). * Ocular medication in either eye of any kind within 30 days of screening. * Central corneal thickness in either eye that is less than 470 µm or greater than 630 µm at screening (or a difference between the eyes \>70 µm). * Any abnormality in either eye preventing reliable applanation tonometry, including aphakic eyes or significant corneal guttatae. * Any other clinically sig…